Toward a disease-sniffing device that rivals a dog’s nose
Numerous studies have shown that trained dogs can detect many kinds of disease — including lung, breast, ovarian, bladder, and prostate cancers, and possibly Covid-19 — simply through smell. In some cases, involving prostate cancer for example, the dogs had a 99 percent success rate in detecting the disease by sniffing patients’ urine samples.
But it takes time to train such dogs, and their availability and time is limited. Scientists have been hunting for ways of automating the amazing olfactory capabilities of the canine nose and brain, in a compact device. Now, a team of researchers at MIT and other institutions has come up with a system that can detect the chemical and microbial content of an air sample with even greater sensitivity than a dog’s nose. They coupled this to a machine-learning process that can identify the distinctive characteristics of the disease-bearing samples.
The findings, which the researchers say could someday lead to an automated odor-detection system small enough to be incorporated into a cellphone, are being published today in the journal PLOS One, in a paper by Claire Guest of Medical Detection Dogs in the U.K., Research Scientist Andreas Mershin of MIT, and 18 others at Johns Hopkins University, the Prostate Cancer Foundation, and several other universities and organizations.
“Dogs, for now 15 years or so, have been shown to be the earliest, most accurate disease detectors for anything that we’ve ever tried,” Mershin says. And their performance in controlled tests has in some cases exceeded that of the best current lab tests, he says. “So far, many different types of cancer have been detected earlier by dogs than any other technology.”
What’s more, the dogs apparently pick up connections that have so far eluded human researchers: When trained to respond to samples from patients with one type of cancer, some dogs have then identified several other types of cancer — even though the similarities between the samples weren’t evident to humans.
These dogs can identify “cancers that don’t have any identical biomolecular signatures in common, nothing in the odorants,” Mershin says. Using powerful analytical tools including gas chromatography mass spectrometry (GCMS) and microbial profiling, “if you analyze the samples from, let’s say, skin cancer and bladder cancer and breast cancer and lung cancer — all things that the dog has been shown to be able to detect — they have nothing in common.” Yet the dog can somehow generalize from one kind of cancer to be able to identify the others.
Mershin and the team over the last few years have developed, and continued to improve on, a miniaturized detector system that incorporates mammalian olfactory receptors stabilized to act as sensors, whose data streams can be handled in real-time by a typical smartphone’s capabilities. He envisions a day when every phone will have a scent detector built in, just as cameras are now ubiquitous in phones. Such detectors, equipped with advanced algorithms developed through machine learning, could potentially pick up early signs of disease far sooner than typical screening regimes, he says — and could even warn of smoke or a gas leak as well.
In the latest tests, the team tested 50 samples of urine from confirmed cases of prostate cancer and controls known to be free of the disease, using both dogs trained and handled by Medical Detection Dogs in the U.K. and the miniaturized detection system. They then applied a machine-learning program to tease out any similarities and differences between the samples that could help the sensor-based system to identify the disease. In testing the same samples, the artificial system was able to match the success rates of the dogs, with both methods scoring more than 70 percent.
The miniaturized detection system, Mershin says, is actually 200 times more sensitive than a dog’s nose in terms of being able to detect and identify tiny traces of different molecules, as confirmed through controlled tests mandated by DARPA. But in terms of interpreting those molecules, “it’s 100 percent dumber.” That’s where the machine learning comes in, to try to find the elusive patterns that dogs can infer from the scent, but humans haven’t been able to grasp from a chemical analysis.
“The dogs don’t know any chemistry,” Mershin says. “They don’t see a list of molecules appear in their head. When you smell a cup of coffee, you don’t see a list of names and concentrations, you feel an integrated sensation. That sensation of scent character is what the dogs can mine.”
While the physical apparatus for detecting and analyzing the molecules in air has been under development for several years, with much of the focus on reducing its size, until now the analysis was lacking. “We knew that the sensors are already better than what the dogs can do in terms of the limit of detection, but what we haven’t shown before is that we can train an artificial intelligence to mimic the dogs,” he says. “And now we’ve shown that we can do this. We’ve shown that what the dog does can be replicated to a certain extent.”
This achievement, the researchers say, provides a solid framework for further research to develop the technology to a level suitable for clinical use. Mershin hopes to be able to test a far larger set of samples, perhaps 5,000, to pinpoint in greater detail the significant indicators of disease. But such testing doesn’t come cheap: It costs about $1,000 per sample for clinically tested and certified samples of disease-carrying and disease-free urine to be collected, documented, shipped, and analyzed he says.
Reflecting on how he became involved in this research, Mershin recalled a study of bladder cancer detection, in which a dog kept misidentifying one member of the control group as being positive for the disease, even though he had been specifically selected based on hospital tests as being disease free. The patient, who knew about the dog’s test, opted to have further tests, and a few months later was found to have the disease at a very early stage. “Even though it’s just one case, I have to admit that did sway me,” Mershin says.
The team included researchers at MIT, Johns Hopkins University in Maryland, Medical Detection Dogs in Milton Keynes, U.K., the Cambridge Polymer Group, the Prostate Cancer Foundation, the University of Texas at El Paso, Imagination Engines, and Harvard University. The research was supported by the Prostate Cancer Foundation, the National Cancer Institute, and the National Institutes of Health.
Reprinted with permission of MIT News. Read the original article.